AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE …
https://www.aktisoncology.com/news/aktis-oncology-raises-84-million-to-advance-novel-targeted-alpha-radiopharmaceuticals%ef%bf%bc/
(August 25, 2022) — Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million.
DA: 61 PA: 33 MOZ Rank: 92